MPN-334 Safety and Efficacy of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis (AdvSM): Results From Part 1 of the Phase 2 Apex Trial | Publicación